Cosentyx and Methotrexate Combination Effects
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, is often used with methotrexate (MTX), a common disease-modifying antirheumatic drug (DMARD). Clinical trials show the combination improves efficacy over either drug alone in psoriatic arthritis (PsA) patients. In the FUTURE 5 trial, adding Cosentyx to stable MTX (15-25 mg/week) increased ACR20 response rates to 70-77% at week 24 (vs. 49% for MTX alone), with similar gains in skin clearance and joint symptom relief.[1][2]
How the Combination Works
Cosentyx blocks IL-17A to reduce inflammation in skin and joints. MTX suppresses broader immune activity via folate inhibition. Together, they target complementary pathways: MTX handles T-cell proliferation while Cosentyx hits downstream cytokines. No pharmacokinetic interactions occur—Cosentyx exposure stays unchanged with MTX.[3]
Efficacy in Key Trials
- Psoriatic Arthritis: FUTURE 2 and 5 trials confirmed higher PASI 90 skin responses (up to 70%) and sustained joint remission when combined vs. monotherapy.[1]
- Rheumatoid Arthritis: Exploratory data showed modest add-on benefits, but Cosentyx isn't approved for RA.[4]
- Long-term: Up to 5 years of data show maintained efficacy without new safety signals.[2]
Safety and Side Effects
Combination increases infection risk slightly (upper respiratory, nasopharyngitis: 40-50% incidence), but rates match monotherapy. No excess serious infections or malignancies vs. MTX alone. Monitor liver enzymes and blood counts due to MTX. Contraindicated in active infections or IBD history.[3][5]
Who Uses This Combo and Dosing
Rheumatologists prescribe it for PsA patients on stable MTX failing monotherapy. Standard: Cosentyx 150-300 mg subcutaneous every 4 weeks (after loading) + unchanged MTX dose. Not recommended for new MTX starters.[6]
When Does the Patent Expire?
Cosentyx patents extend to 2031-2033 in major markets; no biosimilars yet. Check DrugPatentWatch.com for litigation updates.[7]
Sources
[1] N Engl J Med - FUTURE 5 Trial (2018)
[2] Ann Rheum Dis - Long-term FUTURE 5 (2019)
[3] Cosentyx USPI (FDA, 2023)
[4] Arthritis Res Ther (2018)
[5] Novartis Cosentyx HCP Site
[6] ACR Guidelines PsA (2021)
[7] DrugPatentWatch.com